Pharma BD Deal Intelligence
A $145M bet on a near-term pain-drug approval turned into a 4.5-year regulatory ordeal — Dyloject launched just as Hospira itself was swallowed by Pfizer, then was quietly discontinued
Full analysis, sources & comparables →Our Board of Directors, after consultation with our advisors, and in accordance with our merger agreement with MPI, has determined that Hospira's proposal is a…
GaBI Online characterized the merger as a portfolio-fit acquisition leveraging Hospira's existing anesthesiologist call points for Precedex and noted…
Hospira announces successful completion of tender offer for shares of Javelin Pharmaceuticals; all validly tendered shares accepted for payment, with a…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Hospira to acquire Javelin Pharmaceuticals for ~$145M, adding Dyloject IV pain product. Tender offer completed July 1, 2010.
A $145M bet on a near-term pain-drug approval turned into a 4.5-year regulatory ordeal — Dyloject launched just as Hospira itself was swallowed by Pfizer, then was quietly discontinued
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hospira Inc. / Javelin Pharmaceuticals, Inc. (this deal) | 2010 | $145M | 25 |
| Hospira Inc. / Abbott Hospital Products Division | 2004 | — | 54 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals (Generic Injectables Business) | 2010 | $400M | 23 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (API and R&D facilities) | 2012 | $200M | 22 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (Generic Injectables business) | 2009 | $400M | 22 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
← Browse all deals · How we score deals
More: 2010 deals · Hospira Inc. deals · Other deals